Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer withdraws sickle cell drug Oxbryta
Pfizer’s Sickle Cell Drug Candidates Not Hit by Oxbryta Pull
European regulators suspended the approval of Pfizer Inc.’s sickle cell anemia drug, Oxbryta, citing a higher rate of disease complications in patients who started taking the drug.The move comes less than a day after Pfizer abruptly announced a worldwide withdrawal of the drug,
What the withdrawal of its sickle cell drug means for Pfizer, patients, and the FDA
Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and scrambling for ways to notify their patients about a drug that has long divided the community.
FDA alerts patients about Pfizer's Oxbryta withdrawal
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's sickle cell disease treatment Oxbryta.
9h
Can Pfizer Stock Rise 2x To $60?
Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...
STAT
21h
Pharmalittle: We’re reading about Pfizer pulling a sickle cell pill, Moderna getting scolded, and more
Sound familiar? So here are some items of interest. Have a great day, everyone. …
Pfizer
is removing Oxbryta, a pill for ...
MarketWatch
1h
Pfizer Inc. stock rises Thursday, still underperforms market
Shares of
Pfizer
Inc. PFE inched 0.14% higher to $28.97 Thursday, on what proved to be an all-around positive trading ...
1d
Pfizer Is Rising Past Covid-19
Pfizer Inc. ( PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and ...
9h
on MSN
Slow progress on Pfizer's plan to sell drugs to low-income nations at not-for-profit price, says CEO
Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...
1d
Pfizer yanks sickle-cell treatment worldwide after possible link to deaths
Pfizer Inc. said late Wednesday it was withdrawing a sickle-cell drug from markets worldwide and discontinuing clinical ...
labiotech
1d
How Pfizer’s decision in the ’90s cost them a stronghold in the GLP-1 market
Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...
1d
on MSN
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Oxbryta
sickle cell drug
COVID
vaccine
European Union
Feedback